Sarissa Capital Management Lp Exits Position in ANI Pharmaceuticals Inc (ANIP)

ANI Pharmaceuticals Inc (ANIP) : Sarissa Capital Management Lp has sold out all of its stake in ANI Pharmaceuticals Inc during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 31,000 shares of ANI Pharmaceuticals Inc which is valued at $2,156,980.

Other Hedge Funds, Including , Lazard Asset Management sold out all of its stake in ANIP during the most recent quarter. The investment firm sold 7,606 shares of ANIP which is valued $529,225. Thrivent Financial For Lutherans added ANIP to its portfolio by purchasing 3,660 company shares during the most recent quarter which is valued at $254,663. Lasalle Street Capital Management added ANIP to its portfolio by purchasing 4,383 company shares during the most recent quarter which is valued at $256,712. ANI Pharmaceuticals Inc makes up approx 0.24% of Lasalle Street Capital Management’s portfolio. Lasalle Street Capital Management added ANIP to its portfolio by purchasing 4,383 company shares during the most recent quarter which is valued at $256,712. ANI Pharmaceuticals Inc makes up approx 0.24% of Lasalle Street Capital Management’s portfolio.

ANI Pharmaceuticals Inc opened for trading at $59.63 and hit $63 on the upside on Thursday, eventually ending the session at $61.42, with a gain of 2.81% or 1.68 points. The heightened volatility saw the trading volume jump to 5,70,217 shares. Company has a market cap of $708 M.

On the company’s financial health, ANI Pharmaceuticals Inc reported $1.11 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $0.77. The company had revenue of $31.30 million for the quarter, compared to analysts expectations of $27.63 million. The company’s revenue was up 60.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.55 EPS.

Many Wall Street Analysts have commented on ANI Pharmaceuticals Inc. Raymond James Initiated ANI Pharmaceuticals Inc on Jun 23, 2016 to “Strong Buy”, Price Target of the shares are set at $68.ANI Pharmaceuticals Inc was Downgraded by Standpoint Research to ” Hold” on May 24, 2016.

ANI Pharmaceuticals Inc. (ANI) is an integrated specialty pharmaceutical company engaged in developing manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include narcotics oncolytics (anti-cancers) hormones and steroids and complex formulations involving release and combination products. The Company has two pharmaceutical manufacturing facilities located in Baudette Minnesota that are capable of producing oral solid dose products as well as liquids and topicals narcotics and potent products. The Company’s branded products consist of Cortenema Lithobid Reglan and Vancocin. Its generic products include Esterified Estrogen with Methyltestosterone Fluvoxamine Maleate Hydrocortisone Enema Methazolamide Metoclopramide and Opium Tincture. The Company’s markets include hormone and steroidal drugs oncolytics and narcotics and complex formulations including extended release and combination products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *